- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06181227
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
A Phase 2 Study to Evaluate the Safety and Treatment Effect of Intravitreal AVD-104 in Participants With Diabetic Macular Edema
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective is to evaluate the tolerability and treatment effect of intravitreal injections (IVT) of AVD-104 in participants with diabetic macular edema (DME). Participants will receive either three intravitreal injections of low-dose AVD-104 (1.0 mg) each 28 days apart or two intravitreal injections of AVD-104 at a high-dose (2.0 mg) 56 days apart. Serial optical coherence tomography (OCT), ultra wide-field fluorescein angiography, and OCT-angiography (OCT-A) will be performed to evaluate the treatment effect on central subfield thickness (CST) and areas of non-perfusion. All participants will be followed-up for safety until day 84.
There will be a planned enrollment up to 30 participants.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Erie, Pennsylvania, United States, 16507
- Erie Retina Research
-
-
Texas
-
Dallas, Texas, United States, 75231
- Texas Retina Associates
-
Wichita Falls, Texas, United States, 76309
- West Texas Retina Consultants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of diabetes mellitus (type 1 or 2), as defined by the World Health Organization and/or American Diabetes Association
- Decreased visual acuity (VA) due to DME, with BCVA letter score of 75-20 letters on ETDRS-like charts (20/32-20/320 Snellen equivalent)
- DME represented by macular thickening on SD-OCT involving the center of the macula: CST ≥325 μm
Exclusion Criteria:
- Any IVT anti-vascular endothelial growth factor (VEGF) treatment within 3 months before randomization
- Any history of pan-retinal photocoagulation (PRP) treatment
- Any use of Iluvien® (Alimera Sciences, Inc., Alpharetta, GA) in the last 3 years; or Ozurdex® (Abbvie, Chicago, IL) or Xipere (Bausch & Lomb, Vaughan, Ontario, Canada) in the last 6 months
- History of macular laser photocoagulation
- Any signs of high-risk proliferative diabetic retinopathy (PDR)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose AVD-104
Three intravitreal injections at 1.0 milligram per eye each 28 days apart will be administered to the study eye.
Participants will be followed for 84 days total.
|
An intravitreal injection of 50 microliters at the doses described will be given.
Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
|
Experimental: High dose AVD-104
Two intravitreal injections at 2.0 milligrams per eye 56 days apart will be administered to the study eye.
Participants will be followed for 84 days total.
|
An intravitreal injection of 50 microliters at the doses described will be given.
Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of AVD-104
Time Frame: 3 months
|
Number of participants with any evidence of adverse or serious adverse events as assessed by ocular examination
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect
Time Frame: 3 months
|
Evaluate the treatment effect of AVD-104 at multiple doses on central subfield thickness (CST) as measured by Spectral-domain optical coherence tomography (SD-OCT)
|
3 months
|
Treatment effect - vision
Time Frame: 3 months
|
Evaluate the treatment effect of AVD-104 at multiple doses on Best-corrected visual acuity (BCVA) using ETDRS ((Early-Treatment Diabetic Retinopathy Study) visual acuity charts
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AVD-104-C301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on AVD-104
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States
-
Sun Yat-sen UniversityNot yet recruiting
-
University of PittsburghWithdrawnChronically (i.e. Implanted for at Least Six Months) Dual-chamber Pacemaker | Stable Cardiac Status (i.e. no Hospitalizations or Cardiac Medication Changes Within 3 Months)United States
-
ACADIA Pharmaceuticals Inc.Completed
-
Otonomy, Inc.Completed
-
Addpharma Inc.Recruiting
-
Akesobio Australia Pty LtdUnknown
-
AlizymeCompleted
-
Santen Pharmaceutical Co., Ltd.CompletedOcular Hypertension | Open-Angle GlaucomaJapan